1. Biochemistry and Chemical Biology
  2. Cancer Biology
Download icon

Targeting RAS driven human cancer cells with antibodies to upregulated and essential cell-surface proteins

  1. Alexander John Martinko
  2. Charles Truillet
  3. Olivier Julien
  4. Juan Diaz
  5. Max A Horlbeck
  6. Gordon Whiteley
  7. Josip Blonder
  8. Jonathan S Weissman
  9. Sourav Bandyopadhyay
  10. Michael Evans
  11. James A Wells  Is a corresponding author
  1. University of California, San Francisco, United States
  2. Frederick National Laboratory for Cancer Research, United States
Research Article
  • Cited 32
  • Views 8,633
  • Annotations
Cite this article as: eLife 2018;7:e31098 doi: 10.7554/eLife.31098

Abstract

While there have been tremendous efforts to target oncogenic RAS signaling from inside the cell, little effort has focused on the cell-surface. Here, we used quantitative surface proteomics to reveal a signature of proteins that are upregulated on cells transformed with KRASG12V, and driven by MAPK pathway signaling. We next generated a toolkit of recombinant antibodies to seven of these RAS induced proteins. We found that five of these proteins are broadly distributed on cancer cell lines harboring RAS mutations. In parallel, a cell-surface CRISPRi screen identified integrin and Wnt signaling proteins as critical to RAS transformed cells. We show that antibodies targeting CDCP1, a protein common to our proteomics and CRISPRi datasets, can be leveraged to deliver cytotoxic and immunotherapeutic payloads to RAS transformed cancer cells and report for RAS signaling status in vivo. Taken together, this work presents a technological platform for attacking RAS from outside the cell.

Data availability

The following previously published data sets were used

Article and author information

Author details

  1. Alexander John Martinko

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4025-959X
  2. Charles Truillet

    Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  3. Olivier Julien

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7068-7299
  4. Juan Diaz

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  5. Max A Horlbeck

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3875-871X
  6. Gordon Whiteley

    Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, United States
    Competing interests
    No competing interests declared.
  7. Josip Blonder

    Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, United States
    Competing interests
    No competing interests declared.
  8. Jonathan S Weissman

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2445-670X
  9. Sourav Bandyopadhyay

    Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3120-923X
  10. Michael Evans

    Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  11. James A Wells

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    For correspondence
    jim.wells@ucsf.edu
    Competing interests
    James A Wells, Celgene Corp provided some of the funding for this work.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8267-5519

Funding

National Institutes of Health (CA191018)

  • Alexander John Martinko
  • Olivier Julien
  • James A Wells

Celgene (GM097316)

  • Alexander John Martinko
  • James A Wells

National Institutes of Health (GM097316)

  • Alexander John Martinko
  • Olivier Julien
  • James A Wells

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (AN110806-03C) of the University of California San Francisco. Animals that were studied with PET/CT were anesthitized with a mixture of isoflurane/oxygen and humanely euthanized with CO2(g).

Reviewing Editor

  1. Jeffrey Settleman, Calico Life Sciences, United States

Publication history

  1. Received: August 9, 2017
  2. Accepted: January 4, 2018
  3. Accepted Manuscript published: January 23, 2018 (version 1)
  4. Version of Record published: February 2, 2018 (version 2)

Copyright

© 2018, Martinko et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8,633
    Page views
  • 1,513
    Downloads
  • 32
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Biochemistry and Chemical Biology
    Astrid Kollewe et al.
    Research Article Updated

    The transient receptor potential melastatin-subfamily member 7 (TRPM7) is a ubiquitously expressed membrane protein consisting of ion channel and protein kinase domains. TRPM7 plays a fundamental role in the cellular uptake of divalent cations such as Zn2+, Mg2+, and Ca2+, and thus shapes cellular excitability, plasticity, and metabolic activity. The molecular appearance and operation of TRPM7 channels in native tissues have remained unresolved. Here, we investigated the subunit composition of endogenous TRPM7 channels in rodent brain by multi-epitope affinity purification and high-resolution quantitative mass spectrometry (MS) analysis. We found that native TRPM7 channels are high-molecular-weight multi-protein complexes that contain the putative metal transporter proteins CNNM1-4 and a small G-protein ADP-ribosylation factor-like protein 15 (ARL15). Heterologous reconstitution experiments confirmed the formation of TRPM7/CNNM/ARL15 ternary complexes and indicated that complex formation effectively and specifically impacts TRPM7 activity. These results open up new avenues towards a mechanistic understanding of the cellular regulation and function of TRPM7 channels.

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression
    Fang Huang et al.
    Research Article

    The positive transcription elongation factor b (P-TEFb) is a critical co-activator for transcription of most cellular and viral genes, including those of HIV. While P-TEFb is regulated by 7SK snRNA in proliferating cells, P-TEFb is absent due to diminished levels of CycT1 in quiescent and terminally differentiated cells, which has remained unexplored. In these cells, we found that CycT1 not bound to CDK9 is rapidly degraded. Moreover, productive CycT1:CDK9 interactions are increased by PKC mediated phosphorylation of CycT1 in human cells. Conversely, dephosphorylation of CycT1 by PP1 reverses this process. Thus, PKC inhibitors or removal of PKC by chronic activation results in P-TEFb disassembly and CycT1 degradation. This finding not only recapitulates P-TEFb depletion in resting CD4+ T cells but also in anergic T cells. Importantly, our studies reveal mechanisms of P-TEFb inactivation underlying T cell quiescence, anergy, and exhaustion as well as proviral latency and terminally differentiated cells.